Eltoprazine

Eltoprazine

Clinical data
Other names	DU-28,853; DU-28853
Identifiers
IUPAC name 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine
CAS Number	98224-03-4
PubChem CID	65853
ChemSpider	59265
UNII	510M006KO6
ChEMBL	ChEMBL282614
CompTox Dashboard (EPA)	DTXSID5048425
Chemical and physical data
Formula	C12H16N2O2
Molar mass	220.272 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1)C2=C3C(=CC=C2)OCCO3
InChI InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2 Key:WVLHGCRWEHCIOT-UHFFFAOYSA-N

Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent. It acts as an agonist of the serotonin 5-HT_1A and 5-HT_1B receptors and as an antagonist of the serotonin 5-HT_2C receptor. The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022. It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued. Eltoprazine was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay.

External links

• Media related to Eltoprazine at Wikimedia Commons
• Eltoprazine - AdisInsight